공시 • May 21
Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 16, 2026 Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 16, 2026. Location: the offices of shakespeare martineau llp, c o ampa holdings llp, level 19, the shard, 32 london bridge street, se1 9sg, london United Kingdom Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director John Treacy was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Apr 02
Cizzle Biotechnology Holdings Plc announced that it expects to receive £0.25 million in funding Cizzle Biotechnology Holdings Plc announced a private placement of unsecured convertible loan notes for gross proceeds of up to £250,000 on April 2, 2026. The transaction will include participation from existing investor Frazer Lang. The notes will be draw down as to £100,000 on May 1, 2026, £100,000 on June 1, 2026, and £50,000 on July 1, 2026. The notes will now be convertible at £.014 per ordinary share at any time up to October 30, 2026. No interest or fees are payable on the notes. In connection with the transaction, the company has issued warrants to Frazer Lang over 10,000,000 ordinary shares at an exercise price of £0.025, to be exercised within two years from the date of issue, bringing his total warrant holding to 22,500,000 warrants. 공시 • Feb 24
Cizzle Biotechnology Holdings plc Provides an Update on Progress Towards the Accreditation and Launch of Its Proprietary Test for the Ciz1b Biomarker Test Cizzle Biotechnology Holdings Plc provided an update on progress towards the accreditation and launch of its proprietary test for the CIZ1B biomarker which is highly associated with early-stage lung cancer. The Company's North American Licensing partner Cizzle Bio Inc. ("BIO") is now in the final stages of the Clinical Laboratory Improvement Amendments ("CLIA") accreditation process and expect to submit an application for approval in second quarter of 2026. Given the positive progress, BIO and the Company have strengthened their commitment with a new payment schedule which includes a further minimum USD 3.5m advanced royalty schedule to reflect the commencement of sales and long-term growth of the test at scale. BIO and the Company have been working on site, together with BIO's clinical testing partner, Omni Health Diagnostics Inc. ("Omni") in their facility in Richardson, Texas, USA to establish operating procedures ahead of submitting a full validation package for CLIA accreditation. On submission, accreditation is usually immediate unless any clarification is sought. As part of the previously agreed advance exclusivity and royalty fees, BIO has to date paid USD590,000 of the guaranteed advance payments of USD 2.4 million due by 31 December 2026. The Company and BIO have now agreed to a minimum of USD 3.5m of guaranteed further payments over the seven years following an extension of the current agreement in 2031. This will ensure that there are guaranteed payments beyond the initial seven year period of the licence and aligned regular payments after the commercial launch of the test. The new schedule of payments reconfirms the Company will receive the remaining USD 1.81m of the initial advance royalty payments due by 31 December 2026". BIO's strategy is to achieve CLIA accreditation and market launch of the Company's CIZ1B biomarker test with its clinical diagnostics partner Omni in the shortest time possible, thus enabling a roll out campaign across North America. The CLIA accreditation process is necessarily detailed requiring rigorous validation following strict operating procedures. The results generated provide information on analytical accuracy and precision, that together with Omni's own quality assurance processes, provide the basis for submitting the accreditation application. Key personnel from the Company have been working alongside Omni's team in the laboratory in Texas, who expect to complete the testing programme shortly. On submission, accreditation are usually immediate unless any clarification is seeking. Following CLIA accreditation, BIO expects immediate take up based on patient requests for early access to the CIZ1B test. BIO will report when first commercial sales have occurred. Additional Guaranteed Royalties and Advance Royalty Payments The Company has now received payments totalling USD 5.81m from BIO for initial exclusivity fees and advanced royalties as part of guaranteed payments due to the Company totaling USD 2.4 million over the period ending 31 December 2026. A revised payment schedule has been agreed whereby the remaining payments of USD 1.81m of The initial guaranteed advance royalty payments will, as previously reported, be paid before the end of 2026. As noted in the Company's Annual Report for 2024, if these payments are delayed or not received, the Company may need to seek alternative funding. These are the minimum royalties to be paid as part of the Company's licensing agreement with BIO, whereby the Company will receive 10% on gross sales over the initial 7-year period of the agreement which commenced on 18 October 2024. As part of committing to the long-term aim of saving lives through early cancer detection, the Company and BIO have now agreement in 2031, equivalent to a minimum of USD 500,000 per year as part of the ongoing 10% royalty on all sales. 공시 • Feb 06
Cizzle Biotechnology Holdings plc Announces Patent Applications That Claim Protection for Methods That Measure the Ciz1b Lung Cancer Biomarker Cizzle Biotechnology announced that patent applications that claim protection for methods that measure the CIZ1B lung cancer biomarker have been granted by the Canadian intellectual property office. The Company has a strong patent portfolio and continues to seek additional protection in other key markets globally. In addition to its existing patent coverage in the USA, a further application is likely to be granted by the United States patent and trademark office in due course. The patent 'Use of a fibrinogen capture agent to detect a CIZ1B variant' concerns a two-step test format developed by Cizzle at the University of York. This test format is licensed to Cizzle Bio Inc. ("BIO") for use in North America and the Caribbean and these new patents will strengthen BIO's position in commercialising the Company's innovative and proprietary technology. The discovery and development of the CIZ1B biomarker test is the product of work by Professor Dawn Coverley, the Company's founder and CSO, and her research team at the University of York. Initially supported by both UK Research and Industry and Charity sector research grants it has been the ambition to translate the laboratory findings into products that benefit future cancer patients in the UK, and elsewhere around the world. Cizzle Biotechnology's patent portfolio and technology know-how enhances the Company's ability to deliver it's global commercial strategy to licence globally its proprietary test for the CIZ1 B biomarker for use in the early detection of lung cancer. The Company's first licence agreement with BIO for North America and the Caribbean, has led to partnerships between BIO and specialist clinical laboratories and hospitals, to enable market penetration that makes the test available to as many clinicians and patients as possible. Cizzle Biotechnology also has been granted patent protection from the European Patent Office and is now focussed on securing partnerships with accredited facilities in the UK and Europe including the NHS. This aligns well with the current NHS cancer plan which aims to dramatically improve cancer survival by increasing the proportion of cancers diagnosed at stages 1 and 2 from half to three-quarters by 2028. This shift towards earlier diagnosis is expected to save 55,000 additional lives per year by 2028. The plan focuses on improving access to diagnosis and treatment, raising awareness of cancer symptoms, and increasing the number of cancers identified through screening, including personalised and risk-stratified approaches. 공시 • Jun 07
Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 30, 2025 Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 30, 2025. Location: the offices of shakespeare martineau llp, 6th floor, 60 gracechurch street, ec3v 0hr, london United Kingdom 